Fosaprepitant

Category: Nausea & Vomiting



Fosaprepitant Overview

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2] See also Aprepitant Casopitant L-733,060 Maropitant Vestipitant References ^ "Drugs.com, FDA Approve...

Read more Fosaprepitant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fosaprepitant

Recent Fosaprepitant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fosaprepitant
  • Capsule: 125mg, 40mg, 80mg, 80mg + 125mg
  • Emulsion: 130mg/18ml (7.2mg/ml)
  • For Suspension: 125mg/kit
  • Injection: 130mg, 150mg/vial
  • Powder: 115mg/vial, 150mg/vial
  • Solution: 125mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fosaprepitant: (21 results)

Showing the first 20, Sorted by National Drug Code
  • 0338-0008 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Baxter Healthcare Corporation
  • 0591-4385 Fosaprepitant 150 mg Intravenous Injection, Powder, Lyophilized, for Solution by Actavis Pharma, Inc.
  • 16714-120 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rxllc
  • 16714-929 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Northstar Rxllc
  • 25021-784 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Sagent Pharmaceuticals
  • 43598-859 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Dr. Reddy's Laboratories Inc.,
  • 43598-948 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Dr. Reddy's Laboratories Inc.,
  • 60505-6105 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Apotex Corp
  • 63323-972 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Fresenius Kabi USA, LLC
  • 67457-888 Fosaprepitant 115 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Mylan Institutional LLC
  • 67457-889 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Mylan Institutional LLC
  • 68001-421 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Bluepoint Laboratories
  • 69097-830 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Cipla USA Inc.
  • 69539-034 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Msn Laboratories Private Limited
  • 69539-181 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Msn Laboratories Private Limited
  • 70625-300 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Sungen Pharma, LLC
  • 70860-780 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Athenex Pharmaceutical Division, LLC.
  • 71288-418 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Meitheal Pharmaceuticals Inc.
  • 71839-104 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Be Pharmaceuticals Inc.
  • 72205-026 Fosaprepitant 150 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Novadoz Pharmaceuticals LLC
  • 1 more results ...

Other drugs which contain Fosaprepitant or a similar ingredient: (4 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 3 August 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA